Chromocell Therapeutics Corp ( (CHRO) ) has shared an announcement.
Channel Therapeutics Corporation announced on May 1, 2025, that its audited financial statements for the fiscal year ending December 31, 2024, contained a going concern emphasis of matter paragraph. This disclosure, required by NYSE American LLC listing rules, does not alter the company’s financial statements or its annual report. The announcement is part of compliance with regulatory requirements and does not imply any changes in the company’s operational or financial status.
More about Chromocell Therapeutics Corp
Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The company’s initial clinical focus is on selectively targeting the sodium ion-channel NaV1.7 for treating various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
YTD Price Performance: 58.33%
Average Trading Volume: 701,453
Technical Sentiment Signal: Buy
Learn more about CHRO stock on TipRanks’ Stock Analysis page.